focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Odd that it was 0700 - normally intraday or after close - and for a smaller amount.
True. But all the great risers have had, shall I say, a questionable background.
and yet sub £500k and main market listing. Should be attractive to someone.
Why? The app is free.
pretty much.
Look at the chart for October 16-18 2019 the last time Glencore did this. Spiked on day of announcement. Dropped back then went nuts on the 18th before keeping the rise going well into November. If the same thing happens this time around you're looking at 3p minimum.
I think £15-20m
and can sell over 135. What did you mean about next week?
I wouldn't go that far. But I do think the tax losses make it a viable multibagger play.
Maybe. But my point still holds. If they become a shell.
I think the point is it can offset £10m tax losses should it become a shell hence it ten bags.
£10k delayed buy
It's not happening
They're not delisting
So according to the @ExactSciences website over 1m cancer patients have used the Oncotype DX test at $4,000 a pop. That's revenue of $4bn. And #TILS Stemprinter is better. https://www.exactsciences.com/innovative-science/oncotype
So the Oncotype DX assay is a 21-gene assay that predicts the likelihood of chemotherapy benefit and 10-year risk of distant recurrence to inform adjuvant treatment decisions in certain women with early-stage invasive breast cancer.It generated $300m annually in revenue for Genomic Health who themselves were bought out for $2.8bn by Exact Sciences.Turns out there's another test will be put forward at ASCO on May 13th - https://www.asco.org/search/site/stemprinter. Now you don't get picked for ASCO unless you're best in class and you certainly don't put up research comparing you to the leader in the field if you're not going to better it.
https://twitter.com/AndrewScottTV/status/1255088898117681152
Robert Peston
Why is Britain not using its testing capacity?
20 April 2020, 12:22pm
Why is Britain not using its testing capacity?Why is Britain not using its testing capacity?
An NHS is worker is tested for coronavirus (Photo: Getty)
Text
Comments
The government's excuse for why it didn't engage in a comprehensive testing and tracking approach to contain Covid-19 after it started to spread throughout the community was that – unlike Germany and South Korea – it did not have the sufficient number of labs to process the tests. Well that excuse is almost exhausted, because testing capacity is increasing rapidly.
Take for example the new super lab being built in Cambridge by AstraZeneca (AZN) and GlaxoSmithKline (GSK), using equipment and technology made in the UK by Primer Design, the molecular diagnostics division of Novacyt.
AZN's chief executive Pascal Soriot tells me that tests will start any day now and that it will have the capacity to process 30,000 tests per day as soon as early May. From a standing start just a couple of weeks ago, a huge new testing facility is close to completion.
However, this expansion of capacity highlights a separate and highly important infrastructure deficiency – which is how to actually test with swabs all the people deemed a priority to test, and then get the swabs to the labs. Because, believe it or not, right now the problem is not that there isn't enough capacity to process the tests, even though that was the glaring problem last month. The bigger problem now is actually testing all the healthcare and key workers – in the police, fire service and so on – who have been promised tests.
The point is that the government, even without the new Cambridge lab, has increased testing capacity to 35,000 tests per day, thanks to the establishment of other new super labs, in Milton Keynes, Alderley Park and Glasgow – to meet the health secretary's target of 100,000 tests per day by the end of April.
But what is striking – and some would say of concern – is that the number of actual tests happening is far below that capacity: on Saturday, the latest day for which testing data is available, there were just 21,626 tests.
More than 20,000 tests is a vast improvement on the 5,000 tests per day being carried out just a few weeks ago, but nowhere near enough to underpin a policy of testing and contact tracing within the community (an approach widespread in Asia where the virus has been better contained than in Europe, which involves testing everyone with symptoms and then putting into isolation all those with whom they've had contact in preceding days).
The ingenuity shown by public and private sectors to increase testing capacity is impressive and reassuring. But for this ingenuity to translate into a system that could make a further dent in the spread of the virus, and even underpin an easing of restrictions on our basic freedoms, many more tests must actually happen.